A Multinational, Randomized, Open-label, Treat-to-Target Trial Comparing Insulin Degludec and Insulin Glargine in Insulin-Naïve Patients with Type 2 Diabetes Mellitus

Assessing Rates of Hypoglycemia as an End Point in Clinical Trials: Table 1

(2015) Douglas B. Muchmore et al.   DIABETES CARE

A meta-analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia

(2015) S. Heller et al.   DIABETIC MEDICINE

Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2015) Silvio E. Inzucchi et al.   DIABETOLOGIA

A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance

(2014) Hanne Haahr et al.   CLINICAL PHARMACOKINETICS

Use of insulin in type 2 diabetes: What we learned from recent clinical trials on the benefits of early insulin initiation

(2014) M. Hanefeld   DIABETES & METABOLISM

Insulin Degludec Versus Insulin Glargine in Type 1 and Type 2 Diabetes Mellitus: A Meta-Analysis of Endpoints in Phase 3a Trials

(2014) Jiten Vora et al.   Diabetes Therapy

Low-Volume Insulin Degludec 200 Units/mL Once Daily Improves Glycemic Control Similarly to Insulin Glargine With a Low Risk of Hypoglycemia in Insulin-Naïve Patients With Type 2 Diabetes

(2013) Stephen C.L. Gough et al.   DIABETES CARE

Prevalence and Control of Diabetes in Chinese Adults

(2013) Yu Xu   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Insulin degludec compared with insulin glargine in insulin-naïve patients with type 2 diabetes: A 26-week, randomized, controlled, Pan-Asian, treat-to-target trial

(2013) Yukiko Onishi et al.   Journal of Diabetes Investigation

Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes: A 1-year, randomized, treat-to-target trial (BEGIN Once Long)

(2012) B. Zinman et al.   DIABETES CARE

Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials

(2012) R. E. Ratner et al.   DIABETES OBESITY & METABOLISM

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

(2012) Alan J Garber et al.   LANCET

Understanding and assessing the impact of treatment in diabetes: the Treatment-Related Impact Measures for Diabetes and Devices (TRIM-Diabetes and TRIM-Diabetes Device)

(2009) Meryl Brod et al.   Health and Quality of Life Outcomes

10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes

(2008) Rury R. Holman et al.   NEW ENGLAND JOURNAL OF MEDICINE